Merck drug Keytruda succeeds in late-stage esophageal cancer trial
- 14-Nov-2018
Merck & Co’s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the US drugmaker said on Wednesday. Keytruda, among a class of medicines called PD-1 inhibitors, is Merck’s top selling drug and has already been approved to treat several forms of […]